Early research (Phase 1)Study completedNCT02613598
What this trial is testing
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
Who this might be right for
Hodgkin's LymphomaLymphoma, Non-Hodgkin
University of Michigan Rogel Cancer Center 15